The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Open accessAbstract
The β-haemoglobinopathies, such as sickle cell disease and β-thalassaemia, are caused by mutations in the β-globin (HBB) gene and affect millions of people worldwide. Ex vivo gene correction in patient-derived haematopoietic stem cells followed by autologous transplantation could be used to cure β-haemoglobinopathies. Here we present a CRISPR/Cas9 gene-editing system that combines Cas9 ribonucleoproteins and adeno-associated viral vector delivery of a homologous donor to achieve homologous recombination at the HBB gene in haematopoietic stem cells. Notably, we devise an enrichment model to purify a population of haematopoietic stem and progenitor cells with more than 90% targeted integration. We also show efficient correction of the Glu6Val mutation responsible for sickle cell disease by using patient-derived stem and progenitor cells that, after differentiation into erythrocytes, express adult β-globin (HbA) messenger RNA, which confirms intact transcriptional regulation of edited HBB alleles. Collectively, these preclinical studies outline a CRISPR-based methodology for targeting haematopoietic stem cells by homologous recombination at the HBB locus to advance the development of next-generation therapies for β-haemoglobinopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, several reports have shown efficient Glu6Val correction in SCD-HSPCs, although correction efficiency can sometimes be linked with off-target INDELs in the same edited population15,16,45,46.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“RNP delivery results in an initially high level of the genome editing machinery followed by rapid decay, leading to a “fast on, fast off” strategy that results in highly efficient editing while minimizing OTEs13–19.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV6 homologous donor DNA templates are an efficient way to deliver donor templates for sensitive primary immune cells, including HSPCs and T-Cells15,35–40.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies have shown that disease-causing genetic errors can be corrected using CRISPR/Cas9 in long-term engrafting HSPCs that are preserved in downstream effector lineages15,16,24,25.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Major progress in delivering to 44 and handling HPSCs has resulted in formidable efficiencies of mutation correction or mitigation 18,45-47 that are expected to be curative.”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
In the citing paper
“Furthermore, CRISPR/Cas9 system holds tremendous promise for gene therapy [46–51]. It can correct causal mutations in the original genome and rescue the disease phenotypes of monogenic disorders permanently, which currently represents the most translatable field in CRISPR/Cas9-mediated disease therapy.”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Gene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-Versus-Leukemia
Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C., et al. (1997) · Science · doi:10.1126/science.276.5319.1719 · Cited by 1,158
Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
Self-citationIsolation of a candidate human hematopoietic stem-cell population.
Baum, C. M., Weissman, I. L., Tsukamoto, A. S., Buckle, A., & Péault, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2804 · Cited by 1,084
Hematopoietic stem cell: self‐renewal versus differentiation
Seita, J., & Weissman, I. L. (2010) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.86 · Cited by 997
Cited by
Sorted by citations
Items 401–500 of 864
Critical Issues in Diamond-Blackfan Anemia and Prospects for Novel Treatment
Li, H., Lodish, H. F., & Sieff, C. A. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.04.005 · Cited by 21
In vitro transcribed sgRNA causes cell death by inducing interferon release
Mu, W., Tang, N., Cheng, C., Sun, W. C., Wei, X., & Wang, H. (2019) · Protein & Cell · doi:10.1007/s13238-018-0605-9 · Cited by 21
Han, Y., Tan, X., Jin, T., Zhao, S., Li, H., Zhang, W., Kurita, R., Nakamura, Y., Liu, J., Li, D., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174788 · Cited by 21
Mouse models in hematopoietic stem cell gene therapy and genome editing
Radtke, S., Humbert, O., & Kiem, H. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113692 · Cited by 22
Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies
Papizan, J. B., Porter, S. N., Sharma, A., & Pruett‐Miller, S. M. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20200096 · Cited by 21
Mesenchymal stromal cells improve the transplantation outcome of CRISPR-Cas9 gene-edited human HSPCs
Crippa, S., Conti, A., Vavassori, V., Ferrari, S., Beretta, S., Rivis, S., Bosotti, R., Scala, S., Pirroni, S., Hernández, R. J., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.011 · Cited by 19
Mukherjee, P., Park, S. H., Pathak, N., Patino, C. A., Bao, G., & Espinosa, H. D. (2022) · ACS Nano · doi:10.1021/acsnano.2c05494 · Cited by 20
Advances in CRISPR/Cas gene therapy for inborn errors of immunity
Liu, X., Li, G., Liu, Y., Zhou, F., Huang, X., & Li, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1111777 · Cited by 21
CRISPR‐Cas9 delivery strategies and applications: Review and update
Severi, A. A., & Akbari, B. (2024) · genesis · doi:10.1002/dvg.23598 · Cited by 23
Moiani, A., Letort, G., Lizot, S., Chalumeau, A., Foray, C., Félix, T., Clerre, D. L., Temburni, S., Hong, P. W.-P., Leduc, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49353-3 · Cited by 21
Combining Engineered Nucleases with Adeno-associated Viral Vectors for Therapeutic Gene Editing
Epstein, B. E., & Schaffer, D. V. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_2 · Cited by 20
Human macrophages and innate lymphoid cells: Tissue-resident innate immunity in humanized mice
Alisjahbana, A., Mohammad, I., Gao, Y., Evren, E., Ringqvist, E. E., & Willinger, T. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113672 · Cited by 22
Lujan, H., Romer, E. J., Salisbury, R. L., Hussain, S. M., & Sayes, C. M. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa028 · Cited by 20
Genome-edited adult stem cells: Next-generation advanced therapy medicinal products
Benabdellah, K., Sánchez-Hernández, S., Aguilar-González, A., Maldonado‐Pérez, N., Gutiérrez-Guerrero, A., Cortijo-Gutierréz, M., Ramos-Hernández, I., Tristán‐Manzano, M., Galindo‐Moreno, P., Herrera, C., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0338 · Cited by 21
Genome-based therapeutic interventions for β-type hemoglobinopathies
Karamperis, K., Tsoumpeli, M. T., Kounelis, F., Koromina, M., Mitropoulou, C., Moutinho, C., & Patrinos, G. P. (2021) · Human Genomics · doi:10.1186/s40246-021-00329-0 · Cited by 20
Rathbone, T., Ates, I., Fernando, L. P., Addlestone, E., Lee, C. M., Richards, V. P., & Cottle, R. N. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0134 · Cited by 23
A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies
Zittersteijn, H. A., Harteveld, C. L., Klaver-Flores, S., Lankester, A. C., Hoeben, R. C., Staal, F. J. T., & Gonçalves, M. A. F. V. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.617780 · Cited by 21
INSERT-seq enables high-resolution mapping of genomically integrated DNA using Nanopore sequencing
Ivančić, D., Mir-Pedrol, J., Jaraba-Wallace, J., Rafel, N., Sánchez-Mejías, A., & Güell, M. (2022) · Genome biology · doi:10.1186/s13059-022-02778-9 · Cited by 22
Applications of CRISPR Cas-9 in Ovarian Cancer Research
Sherazi, S. A. M., Rafique, F., Haris, M., Arshad, A., Qaiser, H., Uzair, M., & Arshad, M. M. U. D. (2023) · Protein and Peptide Letters · doi:10.2174/0929866530666230607104453 · Cited by 20
Gene editing of non-coding regulatory DNA and its application in crop improvement
Chen, Y.-H., Lu, J., Xia, Y., Huang, L., Zhang, C., Liu, Q., & Li, Q. (2023) · Journal of Experimental Botany · doi:10.1093/jxb/erad313 · Cited by 20
Li, B., Li, Q., Qi, Z., Li, Z., Yan, X., Chen, Y., Xu, X., Pan, Q., Chen, Y., Huang, F., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202316323 · Cited by 21
Dudek, A. M., Feist, W. N., Sasu, E. J., Luna, S. E., Ben-Efraim, K., Bak, R. O., Cepika, A.-M., & Porteus, M. H. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.03.002 · Cited by 19
Self-citationTariq, H., Khurshid, F., Khan, M. H., Dilshad, A., Zain, A., Rasool, W., Jawaid, A., Kunwar, D., Khanduja, S., & Akbar, A. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002478 · Cited by 19
Ali, G., Tariq, M. A., Shahid, K., Ahmad, F. J., & Akram, J. (2020) · Gene Therapy · doi:10.1038/s41434-020-0153-9 · Cited by 20
MicroRNA‐2355‐5p regulates γ‐globin expression in human erythroid cells by inhibiting KLF6
Cheng, Y., Shang, X., Chen, D., Pang, D., Zhao, C., & Xu, X. (2020) · British Journal of Haematology · doi:10.1111/bjh.17134 · Cited by 19
Ineffective erythropoiesis in sickle cell disease: new insights and future implications
Nemer, W. E., Godard, A., & Hoss, S. E. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000642 · Cited by 22
Gene therapy of hematological disorders: current challenges
Al-Saif, A. M. (2019) · Gene Therapy · doi:10.1038/s41434-019-0093-4 · Cited by 20
Development and Characterization of a Modular CRISPR and RNA Aptamer Mediated Base Editing System
Collantes, J. C., Tan, V. M., Xu, H., Ruiz-Urigüen, M., Alasadi, A., Guo, J., Tao, H., Su, C., Tyc, K. M., Selmi, T., et al. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0035 · Cited by 18
Huang, P., Chen, S. H., Shiver, A. L., Culver, R. N., Huang, K. C., & Buie, C. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001727 · Cited by 20
The use of adenoviral vectors in gene therapy and vaccine approaches
Araújo, N. M., Rubio, I. G. S., Toneto, N. P. A., Morale, M. G., & Tamura, R. E. (2022) · Genetics and Molecular Biology · doi:10.1590/1678-4685-gmb-2022-0079 · Cited by 20
Park, S. H., Cao, M., & Bao, G. (2023) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2023.100478 · Cited by 18
Modeling Cancer in the CRISPR Era
Ventura, A., & Dow, L. E. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050455 · Cited by 18
The state of gene therapy research in Africa, its significance and implications for the future
Arbuthnot, P. B., Maepa, M. B., Ely, A., & Pepper, M. S. (2017) · Gene Therapy · doi:10.1038/gt.2017.57 · Cited by 20
Antony, J. S., Haque, A. K. M. A., Lamsfus‐Calle, A., Daniel-Moreno, A., Mezger, M., & Kormann, M. (2018) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.10 · Cited by 20
Poly(Lactic-co-Glycolic Acid) Nanoparticle Delivery of Peptide Nucleic Acids In Vivo
Oyaghire, S. N., Quijano, E., Piotrowski-Daspit, A. S., Saltzman, W. M., & Glazer, P. M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0243-0_17 · Cited by 18
A homology independent sequence replacement strategy in human cells using a CRISPR nuclease
Danner, E. W., Lebedin, M. Y., de la Rosa, K., & Kühn, R. (2021) · Open Biology · doi:10.1098/rsob.200283 · Cited by 22
Genome editing of immune cells using CRISPR/Cas9
Kim, S., Hupperetz, C., Kim, C. H., & Kim, C. H. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.245 · Cited by 21
Song, G., Ma, Y., Gao, X., Zhang, X., Zhang, F., Tian, C., Hou, J., Liu, Z., Zhao, Z., & Tian, Y. (2022) · Life Medicine · doi:10.1093/lifemedi/lnac020 · Cited by 17
Editing human hematopoietic stem cells: advances and challenges
Bhoopalan, S. V., Yen, J. S., Levine, R. M., & Sharma, A. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.08.003 · Cited by 18
Selecting for CRISPR-Edited Knock-In Cells
Reuven, N. B., & Shaul, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911919 · Cited by 16
Allen, D. G., Kalter, N., Rosenberg, M., & Hendel, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051329 · Cited by 18
Self-citationBhoopalan, S. V., Suryaprakash, S., Sharma, A., & Włodarski, M. W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1236038 · Cited by 17
Alayoubi, A. M., Khawaji, Z. Y., Mohammed, M. A., & Mercier, F. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05457-2 · Cited by 24
Fard, G. B., Ahmadi, M. H., Gholamin, M., Amirfakhrian, R., Teimourian, E. S., Karimi, M. A., & Bafghi, M. H. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28603 · Cited by 20
Ren, X., Holsteens, K., Li, H., Sun, J., Zhang, Y., Liu, L., Liu, Q., & Ni, J. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9029-9 · Cited by 20
Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease
Ramadier, S., Chalumeau, A., Félix, T., Othman, N., Aknoun, S., Casini, A., Maule, G., Masson, C., Cian, A. D., Frati, G., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.019 · Cited by 17
High-level correction of the sickle mutation amplified in vivo during erythroid differentiationPreprint
Magis, W., DeWitt, M. A., Wyman, S. K., Vu, J. T., Heo, S., Shao, S. J., Hennig, F., Romero, Z. G., Campo-Fernández, B., McNeill, M., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/432716 · Cited by 17
Molaei, Z., Jabbarpour, Z., Omidkhoda, A., & Ahmadbeigi, N. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03848-4 · Cited by 17
From Cells to Organs: The Present and Future of Regenerative Medicine
Wang, Y., & Jang, Y.-Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/5584_2021_657 · Cited by 21
The EHA Research Roadmap: Hematopoietic Stem Cell Gene Therapy
Naldini, L., Cicalese, M. P., Bernardo, M. E., Gentner, B., Gabaldo, M., Ferrari, G., & Aiuti, A. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000671 · Cited by 16
Gene Editing for Inherited Red Blood Cell Diseases
Bustamante, O. Q., Fañanas-Baquero, S., Dessy-Rodríguez, M., Ojeda-Pérez, I., & Segovia, J. C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.848261 · Cited by 20
Correcting inborn errors of immunity: From viral mediated gene addition to gene editing
Castiello, M. C., Ferrari, S., & VILLA, A. M. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101731 · Cited by 16
Recent advancements in gene therapy for sickle cell disease and β-thalassemia
Li, L., & Mandal, P. K. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1468952 · Cited by 23
Bairqdar, A., Karitskaya, P. E., & Stepanov, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413321 · Cited by 17
Genetic Strategies for HIV Treatment and Prevention
Falkenhagen, A., & Joshi, S. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.018 · Cited by 16
Modarai, S., Kanda, S., Bloh, K. M., Opdenaker, L. M., & Kmiec, E. B. (2020) · Gene Therapy · doi:10.1038/s41434-020-00192-z · Cited by 18
Javaid, N., Pham, T. L. H., & Choi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22010397 · Cited by 18
Non-viral ex vivo genome-editing in mouse bona fide hematopoietic stem cells with CRISPR/Cas9
Byambaa, S., Uosaki, H., Ohmori, T., Hara, H., Endo, H., Nureki, O., & Hanazono, Y. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.01.001 · Cited by 15
Rewriting CFTR to cure cystic fibrosis
Maule, G., Ensinck, M. M., Bulcaen, M., & Carlon, M. S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.12.018 · Cited by 17
Uchida, N., Ferrara, F., Drysdale, C. M., Yapundich, M., Gamer, J., Nassehi, T., DiNicola, J., Shibata, Y., Wielgosz, M. M., Kim, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0411 · Cited by 16
Self-citationNovel therapies in β‐thalassaemia
Grech, L., Borg, K., & Borg, J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14918 · Cited by 18
Poletto, É., Colella, P., Vera, L. N. P., Khan, S. A., Tomatsu, S., Baldo, G., & Gomez‐Ospina, N. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.009 · Cited by 18
Burnight, E. R., Bohrer, L. R., Giacalone, J. C., Klaahsen, D., Daggett, H. T., East, J. S., Madumba, R. A., Worthington, K. S., Mullins, R. F., Stone, E. M., et al. (2018) · The CRISPR Journal · doi:10.1089/crispr.2017.0015 · Cited by 17
Gene Therapy for Primary Immunodeficiency
Houghton, B. C., & Booth, C. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000509 · Cited by 19
Uchida, N., Demirci, S., Haro‐Mora, J. J., Fujita, A., Raines, L. N., Hsieh, M. M., & Tisdale, J. F. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.03.007 · Cited by 16
Self-citationThe Fetal-to-Adult Hemoglobin Switch — Mechanism and Therapy
Orkin, S. H. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2405260 · Cited by 18
CRISPR delivery systems for organ-specific targeting: Advances and challenges
Du, J., Wu, Q., Liu, C., Wang, N., & Gong, C. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100048 · Cited by 20
Therapeutic genome editing with engineered nucleases
Haas, S. A., Dettmer‐Monaco, V., & Cathomen, T. (2017) · Hämostaseologie · doi:10.5482/hamo-16-09-0035 · Cited by 15
A Curative DNA Code for Hematopoietic Defects
Porteus, M. H., Pavel-Dinu, M., & Pai, S. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.05.002 · Cited by 15
Self-citationXu, L., Lahiri, P., Skowronski, J., Bhatia, N., Lattanzi, A., & Porteus, M. H. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.07.009 · Cited by 16
Self-citationLi, Z., Wang, X., Janssen, J. M., Liu, J., Tasca, F., Hoeben, R. C., & Gonçalves, M. A. F. V. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1213 · Cited by 14
Developmental history and application of CRISPR in human disease
Liang, P., Zhang, X., Chen, Y., & Huang, J. (2017) · The Journal of Gene Medicine · doi:10.1002/jgm.2963 · Cited by 16
Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice
Hiramoto, T., Li, L. B., Funk, S. E., Hirata, R. K., & Russell, D. W. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.028 · Cited by 16
Advances and Obstacles in Homology-Mediated Gene Editing of Hematopoietic Stem Cells
Salisbury-Ruf, C. T., & Larochelle, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030513 · Cited by 15
Therapeutic and diagnostic relevance of Crispr technology
Ouar, I. E., & Djekoun, A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111487 · Cited by 15
BAR-Seq clonal tracking of gene-edited cells
Ferrari, S., Beretta, S., Jacob, A., Cittaro, D., Albano, L., Merelli, I., Naldini, L., & Genovese, P. (2021) · Nature Protocols · doi:10.1038/s41596-021-00529-x · Cited by 15
CRISPR/Cas9 genome engineering in hematopoietic cells
Sürün, D., von Melchner, H., & Schnütgen, F. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.08.001 · Cited by 16
Skipper, K. A., Nielsen, M. G., Andersen, S., Ryø, L. B., Bak, R. O., & Mikkelsen, J. G. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.02.006 · Cited by 16
Self-citationLentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery Vectors
Arrasate, A., Lopez-Robles, C., Zuazo, M., Baños-Mateos, S., Martín, C., Lamsfus‐Calle, A., & Fertin, M. J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178497 · Cited by 14
Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies
Bauer, D. E., Brendel, C., & Fitzhugh, C. D. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.08.014 · Cited by 15
Genome editing and bioinformatics
Nakamae, K., & Bono, H. U. (2022) · Gene and Genome Editing · doi:10.1016/j.ggedit.2022.100018 · Cited by 14
Treating Sickle Cell Disease: Gene Therapy Approaches
Cavazzana, M., Corsia, A., Brusson, M., Miccio, A., & Semeraro, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022124-022000 · Cited by 15
Orthogonal transcriptional modulation and gene editing using multiple CRISPR-Cas systems
Broksø, A. D., Bendixen, L., Fammé, S., Mikkelsen, K., Jensen, T. I., & Bak, R. O. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.024 · Cited by 14
Self-citationCurrent and future gene therapies for hemoglobinopathies
Brendel, C., & Williams, D. A. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000581 · Cited by 15
Effective therapies for sickle cell disease: are we there yet?
Crossley, M., Christakopoulos, G. E., & Weiss, M. J. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.07.003 · Cited by 18
Gene Therapy for Hemoglobinopathies
Lidonnici, M. R., Scaramuzza, S., & Ferrari, G. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.138 · Cited by 15
Genome editing: a robust technology for human stem cells
Chandrasekaran, A. P., Song, M., & Ramakrishna, S. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2522-0 · Cited by 14
Advances in Sickle Cell Disease Treatments
Pavan, A. R., & dos Santos, J. L. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200610175400 · Cited by 14
Innovative Cell-Based Therapies and Conditioning to Cure RAG Deficiency
VILLA, A. M., Capo, V., & Castiello, M. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.607926 · Cited by 14
Dudek, A. M., & Porteus, M. H. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.005 · Cited by 14
Self-citationEfficient Homology-directed Repair with Circular ssDNA DonorsPreprint
Iyer, S., Mir, A., Vega‐Badillo, J., Roscoe, B. P., Ibraheim, R., Zhu, L. J., Lee, J., Liu, P., Luk, K., Mintzer, E., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/864199 · Cited by 14
Finotti, A., & Gambari, R. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1204536 · Cited by 13
Murugesan, R., Karuppusamy, K. V., Marepally, S. K., & Thangavel, S. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1148693 · Cited by 15
Xiao, Y., Tan, M., Song, J., Huang, Y., Lv, M., Liao, M., Yu, Z., Gao, Z., Qu, S., & Liang, W. (2024) · Forensic Science International Genetics · doi:10.1016/j.fsigen.2024.103045 · Cited by 13
Luna, S. E., Camarena, J., Hampton, J. P., Majeti, K. R., Charlesworth, C. T., Soupène, E., Selvaraj, S., Jia, K., Sheehan, V., Cromer, M. K., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01222-6 · Cited by 17
Self-citationCRISPR/Cas9 gene correction of HbH-CS thalassemia-induced pluripotent stem cells
Yingjun, X., Yuhuan, X., Yuchang, C., Dong-zhi, L., Wang, D., Song, B., Yang, Y. A., Lu, D., Xue, Y., Xiong, Z., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03763-2 · Cited by 13
Canarutto, D., Tucci, F., Gattillo, S., Zambelli, M., Calbi, V., Gentner, B., Ferrua, F., Marktel, S., Migliavacca, M., Barzaghi, F., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.013 · Cited by 14
Diversification of the CRISPR Toolbox: Applications of CRISPR-Cas Systems Beyond Genome Editing
Balderston, S., Clouse, G., Ripoll, J. J., Pratt, G. K., Gasiūnas, G., Bock, J.-O., Bennett, E., & Aran, K. (2021) · The CRISPR Journal · doi:10.1089/crispr.2020.0137 · Cited by 14
CRISPR/Cas9-mediated gene editing. A promising strategy in hematological disorders
Ugalde, L., Fañanas-Baquero, S., Torres-Ruiz, R., Bustamante, O. Q., & Rı́o, P. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2022.11.014 · Cited by 16
Rewriting Human History and Empowering Indigenous Communities with Genome Editing Tools
Fox, K., Rallapalli, K. L., & Komor, A. C. (2020) · Genes · doi:10.3390/genes11010088 · Cited by 13
Metadata
- Authors
- Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., Uchida, N., Hendel, A., Narla, A., Majeti, R., Weinberg, K. I., & Porteus, M. H.
- Affiliations
- Stanford University (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Stanford Medicine (US)
- Corresponding author
- Porteus, Matthew H.
- ORCID
- Venue
- Nature
- Published
- 2016-11-07
- Volume
- 539
- Issue
- 7629
- Pages
- 384-389
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5898607
- OpenAlex
- W2547418311
- Semantic Scholar
- 91eb4c33902b14df9b2974a4ce8dc6e3c3a02125
- Cited by
- 864
- References
- 50
- Citations by year
- 2026: 45 · 2025: 75 · 2024: 80 · 2023: 93 · 2022: 76 · 2021: 120 · 2020: 93 · 2019: 90 · 2018: 99 · 2017: 89 · 2016: 4
- FWCI
- 48.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (5r01ai120766-02, R01-AI120766)
- National Eye Institute (PN2EY018244)
- National Institute of General Medical Sciences (T32GM007266)
- National Institute of Allergy and Infectious Diseases (R01-AI120766, R01AI097320)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- CRISPR/Cas9 genome editing, beta-globin gene, hematopoietic stem cells, sickle cell disease, beta-thalassemia, homologous recombination, adeno-associated virus vectors, Cas9 ribonucleoprotein, autologous transplantation, reporter genes
- MeSH terms
- Gene Editing, Dependovirus, Alleles, Anemia, Sickle Cell, Animals, Cell Differentiation, Cell Separation, Erythrocytes, Female, Flow Cytometry, Hematopoietic Stem Cells, Humans, Microspheres, Mutation, RNA, Messenger, Genetic Therapy, Mice, SCID, Mice, Inbred NOD, beta-Thalassemia, Genes, Reporter, Gene Targeting, Antigens, CD34, Cell Lineage, beta-Globins, Magnets, Homologous Recombination, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
